EP Patent

EP3642230A1 — Treatment of inflammatory diseases with inhibitors of c5a activity

Assigned to InflaRx GmbH · Expires 2020-04-29 · 6y expired

What this patent protects

The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.

USPTO Abstract

The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.

Drugs covered by this patent

avacincaptad-pegol-sodium (AVACINCAPTAD PEGOL SODIUM)

Patent Metadata

Patent number: EP3642230A1
Jurisdiction: EP
Classification: —
Expires: 2020-04-29
Drug substance claim: No
Drug product claim: No
Assignee: InflaRx GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.